FHIR
© HL7.org |
Server Home
|
XIG Home
|
Server Source
|
FHIR
FHIR IG Statistics: FHIR Resources
Version:
All
|
R2
|
R2B
|
R3
|
R4
|
R4B
|
R5
|
R6
Authority:
All
|
hl7
|
ihe
|
national
Realm:
All
|
BNW
|
au
|
be
|
br
|
ca
|
ch
|
cl
|
cr
|
cz
|
de
|
dk
|
ee
|
eu
|
fi
|
fr
|
il
|
in
|
it
|
jp
|
nl
|
no
|
nz
|
pt
|
se
|
sl
|
stt
|
tw
|
uk
|
us
|
uv
|
vn
View:
All
|
Resource Profiles
|
Datatype Profiles
|
Extensions
|
Logical Models
|
CodeSystems
|
ValueSets
|
ConceptMaps
Resources - All Kinds, Realm US, Authority Hl7
16,284 resources
Type:
ActivityDefinition
ActorDefinition
CapabilityStatement
CodeSystem
ConceptMap
ExampleScenario
GraphDefinition
ImplementationGuide
Measure
MessageDefinition
NamingSystem
OperationDefinition
PlanDefinition
Questionnaire
Requirements
SearchParameter
StructureDefinition
StructureMap
TerminologyCapabilities
TestScript
ValueSet
Text:
By Version
R2
: 52
R2B
: 0
R3
: 523
R4
: 15,269
R4B
: 0
R5
: 440
R6
: 0
Start
Prev
Rows 6800 - 7000
Next
Package
Version
Identity
Name/Title
Status
FMM
WG
Date
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.115
Pathological T Stage T4c
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.116
Pathological T Stage T4b
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.117
Pathological T Stage T4a
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.118
Pathological T Stage T4
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.120
N Stage N2C
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.121
T Stage T3c
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.122
T Stage T3b
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.123
T Stage T3a
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.124
Pathological T Stage T3
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.125
T Stage T2c
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.126
T Stage T2b
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.127
T Stage T2a
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.128
Pathological T Stage T2
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.129
Pathological T Stage T1c
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.132
Pathological T Stage T1b
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.135
Pathological T Stage T1a
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.136
Pathological T Stage T1
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.137
Pathological T Stage T1mic
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.139
Pathological T Stage T0
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.142
Cancer Stage III
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.143
Cancer Stage IIIA
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.144
Cancer Stage IIIB
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.145
Cancer Stage IIIC
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.146
Cancer Stage IV
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.147
Cancer Stage IVA
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.148
Cancer Stage IVB
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.149
Cancer Stage IVC
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.151
Cisplatin Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.153
Vinorelbine Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.154
Gemcitabine Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.155
Docetaxel
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.156
Pemetrexed Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.158
Vinblastine Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.160
ECOG Performance Status
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.161
ECOG Performance Status
active
2020-10
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.162
ECOG Performance Status
active
2022-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.164
Karnofsky Performance Status
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.165
Carboplatin Injectable
active
2020-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.166
Paclitaxel
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.168
Doxorubicin Injectable
active
2022-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.169
Irinotecan Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.179
Bevacizumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.181
Methotrexate
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.184
Breast Cancer
active
2022-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.185
Breast Cancer
active
2023-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.191
Cancer Stage II
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.192
Cancer Stage IIA
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.193
Cancer Stage IIB
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.194
Pertuzumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.196
Ixabepilone Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.197
Goserelin
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.200
Epirubicin Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.202
Ramucirumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.204
Letrozole
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.206
Exemestane
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.209
Fluorouracil
active
2024-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.210
Capecitabine Oral
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.222
Aprepitant Oral
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.223
Fosaprepitant Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.255
Colorectal Cancer
active
2021-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.256
Colorectal Cancer
active
2021-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.257
Colorectal Cancer Chemotherapy
active
2023-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.280
Cancer Stage IA
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.281
Cancer Stage IB
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.286
Cancer Stage IIC
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.291
Positive Result
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.292
Negative Result
active
2015-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.300
Pathological N Stage N1C
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.332
Daunorubicin Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.336
Palonosetron Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.341
External Beam Radiotherapy
active
2024-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.349
Metastatic Cancer
active
2023-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.439
T Category
active
2018-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.440
N Category
active
2018-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.441
M Category
active
2018-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.442
TNM Stage Group
active
2018-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.449
Opioids
active
2024-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.492
Pharmacological interventions for depression
active
2024-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.535
Ovarian Cancer
active
2023-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.536
Ovarian Cancer
active
2023-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.537
Fallopian Tube Cancer
active
2022-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.539
Fallopian Tube Cancer
active
2022-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.541
Peritoneal Cancer
active
2022-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.542
Peritoneal Cancer
active
2023-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.547
Cancer Stage 1C
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.555
Gender Female
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.556
Gender Male
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.557
Pathological N Stage N3a
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.558
Pathological N Stage N3b
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.560
Rolapitant Oral
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.599
Obinutuzumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.600
Ofatumumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.602
Neurokinin 1 Receptor Antagonist
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.604
Serotonin Receptor Antagonist
active
2025-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.61
Cetuximab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.63
Panitumumab Injectable
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.81
Palonosetron Oral
active
2024-12
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.88
Lung Cancer
active
2015-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.89
Lung Cancer
active
2023-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.95
M Stage M0
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.97
Pathological M Stage M1
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.98
Pathological M Stage M1a
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1116.99
Pathological M Stage M1b
active
2024-08
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1125.7
PROMIS Depression Assessment
active
2023-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.11
Sleep Apnea
active
2018-05
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.13
Septic Shock due to C. Diff
active
2019-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.15
Body Temperature
active
2022-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.16
Diarrhea Potentially due to CDI
active
2019-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.17
Abdominal Distension
active
2019-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.18
Vomiting potentially due to CDI
active
2019-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.19
Ileus due to infection
active
2019-04
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.20
Clostridium difficile infection
active
2019-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.3
Radiation Therapy Indicators from CPT
active
2017-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.4
Diagnostic Radiology Surrounding Face and Sinus
active
2017-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.5
Ear Surgery Affecting the Tympanic Membrane
active
2017-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.6
Allergic Rhinitis Immunotherapy
active
2017-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.8
Radiology to Head and Sinus
active
2017-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1130.9
Immunotherapy For Allergic Rhinitis
active
2022-03
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1136.63
Aortic Dissection or Ruptured Aortic Aneurysm
active
2024-07
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.1
C2S Alcohol Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.11
C2S Amphetamine Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.12
C2S Cannabis Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.13
C2S Cannabis Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.14
C2S Cannabis Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.15
C2S Cannabis Use DIsorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.16
C2S Cocaine Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.17
C2S Cocaine Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.18
C2S Cocaine Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.19
C2S Hallucinogens
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.2
C2S Alcohol Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.20
C2S Hallucinogens
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.21
C2S Hallucinogens
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.22
C2S Hallucinogens
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.23
C2S HIV/AIDS Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.24
C2S HIV/AIDS Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.25
C2S HIV/AIDS Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.26
C2S HIV/AIDS Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.27
C2S HIV/AIDS Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.28
C2S Inhalants
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.29
C2S Inhalants
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.3
C2S Alcohol Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.30
C2S Inhalants
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.32
C2S Mental Health Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.33
C2S Mental Health Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.34
C2S Mental Health Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.35
C2S Mental Health Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.36
C2S Mental Health Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.38
C2S Opioids
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.39
C2S Opioids
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.4
C2S Alcohol Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.40
C2S Opioids
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.42
C2S Opioids
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.43
C2S Other Psychoactive Substance Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.44
C2S Other Psychoactive Substance Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.45
C2S Other Psychoactive Substance Use Disorder
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.46
C2S Sedative Hypnotic, or anxiolytic related disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.47
C2S Sedative Hypnotic, or anxiolytic related disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.48
C2S Sedative Hypnotic, or anxiolytic related disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.49
C2S Sexuality and reproductive health information sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.5
C2S Alcohol Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.51
C2S Tobacco Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.52
C2S Tobacco Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.53
C2S Tobacco Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.54
C2S Tobacco Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.55
C2S Substance Use Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.56
C2S Substance Use Information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.58
C2S Sensitive Categories
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.59
C2S Opioids
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.6
C2S Amphetamine Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.60
C2S HIV/AIDS information Sensitivity
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.65
Test C2S Alcohol Use Disorders
active
2019-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.67
Test C2S HIV/AIDS Information Sensitivity
active
2019-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.7
C2S Amphetamine Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.8
C2S Amphetamine Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1142.9
C2S Amphetamine Use Disorders
active
2016-09
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.10
Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1002
Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)
active
2023-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1012
S. Typhi Infection (Disorders) (SNOMED)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1016
S. Paratyphi Infection (Disorders) (SNOMED)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1017
S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1021
Dark Urine (SNOMED)
active
2023-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1022
Acute Onset [Qualifier Value] (SNOMED)
active
2024-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1024
Acute Viral Hepatitis (SNOMED)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1027
Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)
active
2023-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1029
Listeriosis [Listeria species] (Organism or Substance in Lab Results)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1030
Meningitis [Unspecified Cause] (ICD10CM)
active
2023-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1032
Encephalitis [Unspecified Cause] (ICD10CM)
active
2023-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1033
Encephalitis [Unspecified Cause] (SNOMED)
active
2023-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1035
Indeterminate or Equivocal Lab Result Value
active
2023-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1037
Smoking Status [Current Nonsmoker] (SNOMED)
active
2024-06
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1040
Organisms (Tests by Unspecified Method)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1041
Organisms (Tests by Culture and Identification)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1044
Candida auris Infection (Tests for Candida auris by Culture and Identification Method)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1045
Candida auris Infection (Tests for Candida auris Nucleic Acid)
active
2023-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1047
Parkinson’s disease (Disorders) (ICD10CM)
active
2024-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1048
Parkinson’s disease (Disorders) (SNOMED)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1049
Parkinsonism [Secondary] (ICD10CM)
active
2024-01
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1050
Parkinsonism [Secondary] (SNOMED)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1065
Consciousness [Decreased Level] (SNOMED)
active
2025-02
us.nlm.vsac
R4
ValueSet/2.16.840.1.113762.1.4.1146.1071
Drug Use [IV Evidence] (SNOMED)
active
2023-01